The immediate delisting threat has been resolved, but the company's fragile equity position (below $5M stockholders' equity) means it cannot rely on a second compliance period if the bid price drops again. Monitor the stock's bid price closely — any sustained dip below $1.00 could trigger a rapid delisting process with no cure period available.
Price Chart
Executive Summary
Medicus Pharma received a delisting determination letter from Nasdaq on October 20, 2026, after failing to meet the $1.00 minimum bid price requirement by the October 19, 2026 compliance deadline and not qualifying for a second 180-day period due to insufficient stockholders' equity. However, on October 23, 2026, Nasdaq issued a compliance notice confirming that the closing bid price had been at or above $1.00 for ten consecutive business days (October 12-23, 2026), superseding the delisting letter and closing the matter. The company remains at risk of future non-compliance with Nasdaq's continued listing requirements.
Key Facts
- Received delisting determination letter on October 20, 2026 for failing to meet $1.00 minimum bid price requirement by October 19, 2026 deadline
- Nasdaq determined company was not eligible for a second 180-day compliance period because it does not meet the minimum $5 million stockholders' equity requirement
- On October 23, 2026, Nasdaq issued a compliance notice confirming bid price had been at or above $1.00 for ten consecutive business days (October 12-23, 2026), superseding the delisting letter
- Company cautions there can be no assurance it will maintain compliance with Nasdaq's continued listing requirements in the future
Financial Impact
Delisting risk averted for now; no direct financial impact disclosed. Future non-compliance could lead to delisting and severe liquidity impairment for a $5M market cap company.
Risk Factors
- Stock price may again fall below $1.00, triggering immediate delisting proceedings with no second compliance period available
- Low stockholders' equity (below $5M) limits the company's ability to pursue a reverse stock split or capital raise to maintain compliance
- Delisting would severely reduce liquidity and institutional ownership, potentially pushing the stock to OTC markets
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001062993-26-005528 |
| Document: 0001062993-26-005528-index-headers.html | 0001062993-26-005528 |
| Document: 0001062993-26-005528-index.html | 0001062993-26-005528 |
| Document: 0001062993-26-005528.txt | 0001062993-26-005528 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $2.60 | awaiting T+1 | — | $2.51 (−3.46%) |
Oct 16, 2026 10d ago | 8-K | $2.66 $2.72 | ▲ +2.45% | ▲ +2.11% | $2.51 (−5.46%) |
Oct 16, 2026 10d ago | SC 13G/A | $2.66 $2.72 | ▲ +2.45% | ▲ +2.11% | $2.51 (−5.46%) |
Oct 7, 2026 19d ago | 8-K | $0.1019 $0.0921 | ▼ −9.62% | ▼ −10.22% | $2.51 (+2363.20%) |
Sep 14, 2026 6w ago | 8-K | $0.1593 $0.1521 | ▼ −4.52% | ▼ −4.06% | $2.51 (+1475.64%) |
Sep 11, 2026 6w ago | 8-K | $0.1626 $0.1593 | ▲ +2.03% | ▲ +1.58% | $2.51 (−1443.67%) |
Sep 10, 2026 6w ago | Press Release | $0.1614 $0.1626 | ▲ +0.74% | ▼ −0.11% | $2.51 (+1455.14%) |
Sep 3, 2026 7w ago | 8-K | $0.1705 $0.1720 | ▲ +0.88% | ▲ +1.27% | $2.51 (+1372.14%) |
Jul 16, 2026 14w ago | Press Release | $0.4060 $0.3758 | ▼ −7.44% | ▼ −6.45% | $2.51 (+518.23%) |
May 14, 2026 23w ago | Press Release | $0.3010 $0.2910 | ▲ +3.32% | ▲ +3.26% | $2.51 (−733.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers